Pravastatin-loaded chitosan nanoparticles: Formulation, characterization and cytotoxicity studies

被引:26
作者
Badran, Mohamed M. [1 ,4 ]
Harisa, Gamaleldin I. [2 ,5 ]
AlQahtani, Saeed A. [2 ]
Alanazi, Fars K. [2 ]
Zoheir, Khairy M. A. [3 ,6 ]
机构
[1] King Saud Univ, Dept Pharmaceut, Coll Pharm, Bldg 23,Off AA 68,POB 2457, Riyadh 11451, Saudi Arabia
[2] King Saud Univ, Dept Pharmaceut, Coll Pharm, Pharmaceut Ind, POB 2457, Riyadh 11451, Saudi Arabia
[3] King Saud Univ, Coll Pharm, Dept Pharmacol, Riyadh, Saudi Arabia
[4] Al Azhar Univ, Coll Pharm, Dept Pharmaceut, Cairo, Egypt
[5] Al Azhar Univ, Coll Pharm, Dept Biochem, Cairo, Egypt
[6] Natl Res Ctr, Dept Cell Biol, Cairo, Egypt
关键词
Chitosan nanoparticles; Pravastatin; Characterization; In vitro release; Cytotoxicity; DRUG-DELIVERY; HEPATOCELLULAR-CARCINOMA; COLORECTAL-CANCER; TUMOR; THERAPY; RELEASE; ERYTHROCYTES; NANOGELS; SURVIVAL; SODIUM;
D O I
10.1016/j.jddst.2016.01.004
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Pravastatin (PRV) loaded Chitosan nanoparticles (PRV/CSNPs) were employed as a novel carriers for liver cancer treatment. These nanoparticles were prepared by an ionic gelation method and characterized by FTIR and XRD. The prepared nanoparticles showed the spherical shape of nanoparticles having an average size of 129.8 +/- 10.5-270.4 +/- 23.3 nm, PDI in the range of 0.238 +/- 0.03-0.452 +/- 0.05 and zeta potential between 25.1 +/- 2.6 and 33.5 +/- 2.7 mV. The PRV entrapment efficiency of CSNPs was in the range of 49.05-72.04%. The in vitro release studies showed an initial rapid PRV release up to 6 h followed by a slow release ranging from 52 to 92% after 48 h following Higuchi's model kinetics. The in vitro cytotoxicity of PRV/CSNPs showed 51% HepG2 growth inhibition compared to 38% of free PRV after 72 h incubation. PRV/CSNPs can be considered as a promising carrier for cancer therapy. (C) 2016 Elsevier B.V. All rights reserved.
引用
收藏
页码:1 / 9
页数:9
相关论文
共 45 条
[1]  
Abdel-Hamid M, 2012, ASIAN J CHEM, V24, P584
[2]   Chitin and chitosan in selected biomedical applications [J].
Anitha, A. ;
Sowmya, S. ;
Kumar, P. T. Sudheesh ;
Deepthi, S. ;
Chennazhi, K. P. ;
Ehrlich, H. ;
Tsurkan, M. ;
Jayakumar, R. .
PROGRESS IN POLYMER SCIENCE, 2014, 39 (09) :1644-1667
[3]   Methotrexate-loaded chitosan nanogels as 'Trojan Horses' for drug delivery to brain: Preparation and in vitro/in vivo characterization [J].
Azadi, Amir ;
Hamidi, Mehrdad ;
Rouini, Mohammad-Reza .
INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES, 2013, 62 :523-530
[4]   Preparation and nanoencapsulation of L-asparaginase II in chitosan-tripolyphosphate nanoparticles and in vitro release study [J].
Bahreini, Elham ;
Aghaiypour, Khosrow ;
Abbasalipourkabir, Roghayeh ;
Mokarram, Ali Rezaei ;
Goodarzi, Mohammad Taghi ;
Saidijam, Massoud .
NANOSCALE RESEARCH LETTERS, 2014, 9 :1-13
[5]   Assessment of sequential combination of 5-fluorouracil-loaded-chitosan-nanoparticles and ALA-photodynamic therapy on He La cell line [J].
Benito-Miguel, Marta ;
Dolores Blanco, Ma ;
Gomez, Clara .
PHOTODIAGNOSIS AND PHOTODYNAMIC THERAPY, 2015, 12 (03) :466-475
[6]   Chitosan-based hydrogels for controlled, localized drug delivery [J].
Bhattarai, Narayan ;
Gunn, Jonathan ;
Zhang, Miqin .
ADVANCED DRUG DELIVERY REVIEWS, 2010, 62 (01) :83-99
[7]   Liposomal pravastatin inhibits tumor growth by targeting cancer-related inflammation [J].
Coimbra, Maria ;
Banciu, Manuela ;
Fens, Marcel H. A. M. ;
de Smet, Lieselotte ;
Cabaj, Magda ;
Metselaar, Josbert M. ;
Storm, Gert ;
Schiffelers, Raymond M. .
JOURNAL OF CONTROLLED RELEASE, 2010, 148 (03) :303-310
[8]  
Dand N., 2013, CYS, V4, P94, DOI [DOI 10.4103/2229-5186.115544, 10.4103/2229-5186.115544]
[9]  
Dash S, 2010, ACTA POL PHARM, V67, P217
[10]  
Deepa N., 2014, NANOBIOTECHNOL, V6, P574